Why Crispr’s Gene-Editing Jump Wasn’t Enough To Help Vertex Stock 2021-06-11T16:38:02-04:00June 11th, 2021| share this article! Vertex Pharmaceuticals and Crispr Therapeutics appeared Friday to be making progress on a cure for two blood diseases. But only CRSP stock popped. Read More share this article! Related Posts Novo Nordisk’s Wegovy Sales More Than Doubled. Why the Stock Is Falling., Go to article May 2nd, 2024 Tesla Stock Could Be $460 or $70 a Share. Here’s How., Go to article May 2nd, 2024 Carvana Was Once Left for Dead. Earnings Show Stock Can’t Be Stopped., Go to article May 2nd, 2024 The Federal Reserve Keeps Its Options Open on Interest Rates, Go to article May 2nd, 2024
